EXPLORE THE SCIENCE
TL;DR: A 2026 protocol posted to medRxiv describes a nationwide Japan survey designed to measure how dementia specialists handle anti-amyloid antibody therapy, biomarker testing, MRI safety monitoring, service capacity, and patient-choice tradeoffs. Key Findin…
Read article
Lecanemab shows promise in treating Alzheimer’s disease by reducing clinical deterioration and amyloid-beta plaques, but it has significant adverse effects and requires further research for confirmation. Highlights: FDA Approval: The US FDA authorized lecanema…
Read article
A new drug recently approved for Alzheimer’s disease aims to treat the underlying cause of the condition by removing amyloid plaques in the brain. Though promising, the drug called aducanumab also comes with potential side effects that require careful monitori…
Read article